ESTRO 2024 - Abstract Book

S1648

Clinical - Lung

ESTRO 2024

33. Immunotherapy for Stage III NSCLC and Extensive Stage Small-Cell Lung Cancer – IMFINZI® (durvalumab). [accessed 15 Sep 2021] Available from: https://www.imfinzi.com/

34. C F-F, D V, T K, D P, L P-A, JF V, et al. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2021 May 1;16(5):860 – 7. [accessed 20 Sep 2021] Available from: https://pubmed.ncbi.nlm.nih.gov/33476803/ 35. Socinski MA, Özgüroğlu M, Villegas A, Daniel D, Vicente D, Murakami S, et al. Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non – Small – Cell Lung Cancer (PACIFIC). Clinical Lung Cancer. 2021;0(0). [accessed 7 Oct 2021] Available from: http://www.clinical-lung cancer.com/article/S1525730421001443/fulltext 36. Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares LG, et al. Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial. https://doi.org/101200/JCO20213915_suppl8511. 2021 May 28;39(15_suppl):8511 – 8511. doi: 10.1200/JCO.2021.39.15_SUPPL.8511 37. G S, Y O, Y T, H K, F D, H M, et al. Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON). Lung cancer (Amsterdam, Netherlands). 2021 Nov;161:86 – 93. [accessed 28 Sep 2021] Available from: https://pubmed.ncbi.nlm.nih.gov/34543942/ 38. NA M, O H, S B, D D. Guideline Concordance With Durvalumab in Unresectable Stage III Non-Small Cell Lung Cancer: A Single Center Veterans Hospital Experience. Federal practitioner : for the health care professionals of the VA, DoD, and PHS. 2021;38(2). [accessed 28 Sep 2021] Available from: https://pubmed.ncbi.nlm.nih.gov/33716483/ 39. A B, L M, C LP, D P. Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real world experience. Therapeutic advances in respiratory disease. 2019;13. [accessed 28 Sep 2021] Available from: https://pubmed.ncbi.nlm.nih.gov/31686616/ 40. Noronha V, Talreja VT, Patil V, Joshi A, Menon N, Mahajan A, et al. Real-World Experience of Patients with Inoperable, Stage III Non-small-Cell Lung Cancer Treated with Durvalumab after Chemoradiotherapy: Indian Experience. South Asian Journal of Cancer. 2020 Jul;9(3):180. [accessed 28 Sep 2021] Available from: /pmc/articles/PMC8357451/ 41. Real-World PFS Benefit Reported With Durvalumab Regimen in Unresectable Stage III NSCLC. [accessed 12 Oct 2021] Available from: https://www.onclive.com/view/real-world-pfs-benefit-reported-with-pacific-regimen-in unresectable-stage-iii-nsclc 42. J E, K de J, LEL H, M van der S, C T, S S, et al. Trends and variations in treatment of stage I-III non-small cell lung cancer from 2008 to 2018: A nationwide population-based study from the Netherlands. Lung cancer (Amsterdam, Netherlands). 2021 May 1;155:103 – 13. [accessed 2 Oct 2021] Available from: https://pubmed.ncbi.nlm.nih.gov/33774382/ 43. Mcdonald F, Senan S, Faivre-Finn C, Hatton M. Curative Radiotherapy for Non-small Cell Lung Cancer: Practice Changing and Changing Practice? Clinical Oncology. 2019 Oct 1;31(10):678 – 80. [accessed 2 Oct 2021] Available from: http://www.clinicaloncologyonline.net/article/S0936655519303371/fulltext